SCHEMBL401392

SCHEMBL401392

NC[C@H](NC(=O)c1ccc(C#Cc2ccc(NC(=O)CNCc3cccnc3)cc2)cc1)C(=O)NO

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 3/20 0.47
EPAS1 Q99814 3/20 0.47
HTT P42858 3/20 0.46
LMNA P02545 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ACACB O00763 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 1/20 0.43
NCOA1 Q15788 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
NAMPT P43490 1/20 0.41
HDAC1 Q13547 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL437693 0.97 HTT (0.44) HIF1AEPAS1HTTLMNANPSR1
SCHEMBL1109377 0.92 HTT (0.48) HTTLMNANPSR1MEN1KMT2A
SCHEMBL403813 0.92 HIF1A (0.45) HIF1AEPAS1HTTLMNANPSR1
SCHEMBL438062 0.89 KDM4E (0.48) HTTLMNAACACBALDH1A1NAMPT
SCHEMBL404968 0.89 RECQL (0.46) ALDH1A1
SCHEMBL1097797 0.88 ACACB (0.52) HIF1AEPAS1ACACBHDAC1
SCHEMBL403816 0.87 MAPK1 (0.44) HIF1AEPAS1NAMPT
SCHEMBL404106 0.86 HTT (0.48) HIF1AEPAS1HTTLMNANPSR1
SCHEMBL399429 0.86 KDM4E (0.47) HTTLMNAACACBALDH1A1NAMPT
SCHEMBL405331 0.86 RECQL (0.44) LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153843-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2012-04-10 US disclosed
US-8153843-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2012-04-10 US disclosed
US-8101640-B2 Antibacterial agents NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2012-01-24 US disclosed
US-8084615-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2011-12-27 US disclosed
US-8084615-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2011-12-27 US disclosed
US-7989660-B2 BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2011-08-02 US disclosed
US-7989660-B2 BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2011-08-02 US disclosed
US-20110172174-A1 Antibacterial agents NOVARTIS VACCINES AND DIAGNOSTICS INC. 2011-07-14 US disclosed
US-20100324025-A1 Antibacterial Agents UNIVERSITY OF WASHINGTON (US) 2010-12-23 US disclosed
US-20100324025-A1 Antibacterial Agents UNIVERSITY OF WASHINGTON (US) 2010-12-23 US disclosed
US-20090247506-A1 Antibacterial agents CHIRON CORPORATION 2009-10-01 US disclosed
US-20090163496-A1 ANTIBACTERIAL AGENTS UNIVERSITY OF WASHINGTON (US) 2009-06-25 US disclosed
US-20090163496-A1 ANTIBACTERIAL AGENTS UNIVERSITY OF WASHINGTON (US) 2009-06-25 US disclosed
US-20080269221-A1 ANTIBACTERIAL AGENTS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2008-10-30 US disclosed
US-20080269221-A1 ANTIBACTERIAL AGENTS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2008-10-30 US disclosed
US-7358359-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2008-04-15 US disclosed
US-7358359-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2008-04-15 US disclosed
US-20070244197-A1 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2007-10-18 US disclosed
US-20070244197-A1 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2007-10-18 US disclosed
US-20060154988-A1 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2006-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244197-A1 Antibacterial agents MRPL21, SI, PGLS HIF1A 2221/4885EPAS1 3481/4885HTT 4781/4885
US-20090247506-A1 Antibacterial agents MRPL21, SI, PGLS HIF1A 2221/4885EPAS1 3481/4885HTT 4781/4885
US-20110172174-A1 Antibacterial agents MRPL21, SI, PGLS HIF1A 2221/4885EPAS1 3481/4885HTT 4781/4885
US-20080269221-A1 ANTIBACTERIAL AGENTS MRPL21, SI, PGLS HIF1A 2221/4885EPAS1 3481/4885HTT 4781/4885
US-20060154988-A1 Antibacterial agents MRPL21, SI, PGLS HIF1A 2221/4885EPAS1 3481/4885HTT 4781/4885
US-20090163496-A1 ANTIBACTERIAL AGENTS MRPL21, SI, PGLS HIF1A 2221/4885EPAS1 3481/4885HTT 4781/4885
US-20100324025-A1 Antibacterial Agents MRPL21, SI, PGLS HIF1A 2221/4885EPAS1 3481/4885HTT 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.